Loading clinical trials...

COMPLETED

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects

NCT01032486•Teva Branded Pharmaceutical Products R&D, Inc.

View on ClinicalTrials.gov

Summary

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•idiopathic Parkinson's disease.
•eligible to Azilect® treatment as per Canadian product monograph

Exclusion Criteria

•exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions) based on the Canadian product monograph.
•investigational drug within 30 days prior to study
•use of Azilect® or selegiline within 60 days prior to study
•significant medical condition

Key Dates

Start Date

December 1, 2009

Primary Completion Date

June 1, 2011

Completion Date

July 1, 2011

Last Updated

August 28, 2013

Enrollment

120

ACTUAL participants

Conditions

Parkinson's Disease

Interventions

Rasagiline mesylate

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Deep Brain Stimulation Therapy in Movement Disorders

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations